Sibutramine: efficacy and safety of prescribing in routine clinical practice

Романцова, Т. И.

doi:10.14341/omet2015318-24

Cited by 12 publications

(5 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…За время наблюдения эпизоды клинически значимого повышения АД (более 10 мм рт.ст. на протяжении 2 последовательных визитов) были зарегистрированы у 26% пациентов, однако это не привело к прекращению приема сибутрамина [10]. В нашем исследовании эпизодов клинически значимого повышения АД выявлено не было, что подтверждалось данными самоконтроля, офисного и суточного измерения АД.…”

Section: Discussionunclassified

The experience of sibutramine administration in patients with obesity and controlled arterial hypertension

Shupenina¹,

Yushchuk²,

Vasyuk³

et al. 2019

Obes. metabol.

View full text Add to dashboard Cite

BACKGROUND: Obesity is a metabolic disorder that becomes epidemic. Visceral adiposity increases the risk of arterial hypertension, diabetes mellitus and other comorbidities. According to this, the main aim of obesity treatment is not only a weight loss but also a decrease of the risk of comorbidities. AIMS: to assess the efficiency and safety of sibutramine in patients with obesity and arterial hypertension, to evaluate the drug influence on epicardial fat thickness. MATERIALS AND METHODS: 57 patients aged 35-60 with obesity and arterial hypertension were included in the study. All patients at the beginning and after 7 months of follow-up underwent complex examination including anthropometric measurement, ECG, office and ambulatory blood pressure measurement, echocardiography. Patients with controlled arterial hypertension were included. During the first month of follow-up patients were given general weight loss recommendations. Then sibutramine was added. Control visits to assess efficiency and safety of drug treatment were held after 1 and 6 months of follow-up. RESULTS: Women predominated among the study participants. Visceral adiposity was approved by anthropometric measurements among all patients. Most patients had impaired left ventricle geometry: concentric remodeling or hypertrophy. During the first month of follow-up the weight loss was mild: 2 kg (less than 2%) in average. Sibutramine for 1 month the weight loss increased: 3.7 kg (more than 2%) in average. After 6 months of drug administration the weight loss of patients consisted 8.6 kg (6.2%) in average. According to echocardiography results indexed mass of LV myocardium decreased in all patients more significantly in women. Also in this group of patients significant decrease of epicardial fat thickness was revealed. Adverse events of sibutramine were revealed in 26.3% of patients. The most frequent were constipation (12.3%) and dry mouth (10.6%). The severity of symptoms persisted for 1 month and then decreased, additional therapy was not required. CONCLUSIONS: Sibutramine treatment of obesity promotes effective weight loss, influences the adipose tissue distribution, decreases the progress of associated comorbidities. Sibutramine is an effective and safe drug that can be used in patients with visceral adiposity and controlled arterial hypertension.

show abstract

Section: Discussionunclassified

The experience of sibutramine administration in patients with obesity and controlled arterial hypertension

Shupenina¹,

Yushchuk²,

Vasyuk³

et al. 2019

Obes. metabol.

View full text Add to dashboard Cite

show abstract

“…Данный эффект не характерен для лираглутида, который снижает массу тела и уменьшает жировую массу, уменьшая чувство голода и понижая расход энергии [7,11] Таким образом, препарат для снижения массы тела Редуксин форте отвечает основным характеристикам эффективного и безопасного препарата, а также обладает рядом дополнительных преимуществ в отношении восстановления метаболического здоровья и нормализации пищевого поведения. Наличие в арсенале отечественных специалистов российского препарата позволит сохранить доступность терапии, улучшить прогноз и качество жизни пациентов с избыточной массой тела и ожирением [3,8,12].…”

Section: современные возможности терапии пациентов с ожирением и избы...unclassified

Modern possibilities of therapy for obese and overweight patients in the new reality

Ametov,

Garieva,

Ozdemirova

2023

Endocrinology: News, Opinions, Training

View full text Add to dashboard Cite

Obesity is one of the most common diseases in economically developed countries, leading to the development of type 2 diabetes mellitus and cardiovascular diseases. The central place in the treatment of obesity is occupied by property selected drug therapy. Evidence from this clinical case the efficacy of treatment for overweight and obese patients with a fixed combination of sibutramine and metformin is shown, which demonstrates the feasibility of using Reduxin forte as well as a logical pharmacotherapy option when canceling liraglutide.Funding. The study had no sponsor support. Conflict of interest. The authors declare no conflict of interest.

show abstract

“…Сибутрамин оказывает влияние на структуры центральной нервной системы, реализующие гомеостатический, когнитивный и эмоциональный контроль пищевого поведения. Усиление термогенеза на фоне применения сибутрамина устраняет характерное при снижении массы тела замедление скорости основного обмена, что вносит дополнительный вклад в достижение отрицательного энергобаланса [28]. Эффективность и безопасность Редуксина при назначении в рутинной клинической практике для лечения ожирения, в том числе у больных СД2, были подтверждены в ходе Всероссийской наблюдательной программы «ВЕСНА»; выборка включала свыше 34 000 пациентов.…”

Section: эффективность редуксина в лечении сд2 и ожиренияunclassified

Rational approach to patients treatment with type 2 diabetes and obesity: results of the All-Russian observational program «AURORA»

et al. 2019

View full text Add to dashboard Cite

Background: As in many other developed nations, the problem of obesity and type 2 diabetes is acute in Russia. In Russia, the only combination of sibutramine and metformine (ReduxinMet) is authorized to reduce body mass and prevention development of type 2 diabetes mellitus or its complication. The article presents the results of the observational program AVRORA. Aim: Evaluation of the effectiveness and safety of ReduxinMet (sibutramine + microcrystalline cellulose + Metformin) in patients with type 2 diabetes and alimentary obesity in routine clinical practice. Materials methods: The observational program AVRORA was conducted from September 2016 to October 2017 under the auspices of the Endocrinological Scientific Center and the Russian Association of Endocrinologists. The AVRORA program was a multicenter, non-interventional study of patients to whom the attending physicians prescribed ReduxinMet, a set (tablets + capsules), in accordance with the instruction for medical use as part of routine clinical practice. The treated group included patients of both sexes, aged 1865 years, with an established diagnosis of obesity in combination with type 2 diabetes. The duration of the drug usage was determined by the attending physician and was up to 6 months. ReduxineMet was prescribed in addition to the existing glucose-lowering therapy, the dose of metformin was adjusted to the patient's needs. Results: The AVRORA study was attended by 259 doctors and 5,812 patients in 240 medical institutions from 12 cities of the Russian Federation. The average age of patients was 46.6 10.5 years, the ratio of male / female -24% / 76%. The decreasing of BMI during 6 months of the therapy amounted to 5.4 2.3 kg / m2 (on average, 15.1 6.4 kg). After 3 months of the therapy 81.6% of patients achieved clinically significant weight loss of 10.6% or more. The average decrease in waist circumference during 6 months of therapy was 13.8 7.4 cm. A decrease of indicators of glycemic control and lipid metabolism right up to the target values was observed. Conclusions: In AVRORA study it was shown that addition of ReduxineMet (sibutramine+ microcrystalline cellulose+metformine) to the complex therapy of the diabetes in combination with obesity according to approved indications is safe and effective for long-term treatment in regards to weight loss, regulation of lipemic index, glucose profile and quality of life.

show abstract

Sibutramine: efficacy and safety of prescribing in routine clinical practice

Cited by 12 publications

References 44 publications

The experience of sibutramine administration in patients with obesity and controlled arterial hypertension

The experience of sibutramine administration in patients with obesity and controlled arterial hypertension

Modern possibilities of therapy for obese and overweight patients in the new reality

Rational approach to patients treatment with type 2 diabetes and obesity: results of the All-Russian observational program «AURORA»

Contact Info

Product

Resources

About